BioCentury | Jan 6, 2021
Management Tracks

Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more

...new role as chief corporate development officer at the diagnostics company.Robert Dolski joined immuno-oncology company Checkmate Pharmaceuticals Inc....
...the board at Radius Health Inc. (NASDAQ:RDUS). Jessica Hopfield and Tony Rosenberg stepped down from the board. BC Staff Nektar PureTech Novacyt Checkmate Pharma Radius...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...Aled Williams as CBO. Williams was most recently chief commercial officer at VectivBio AG.Oncology company Checkmate Pharmaceuticals Inc....
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...Syncona company, Orbit Biomedical Ltd., has been merged into Gyroscope (see “Syncona’s Sister Act” ). Checkmate Pharmaceuticals Inc....
...that gives it a dual listing. Targets TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Freeline Therapeutics Checkmate Pharmaceuticals Inc. Arya...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...“Crossovers Pile In” ). More IPO news Two more biotechs, Freeline Therapeutics Holdings plc and Checkmate Pharmaceuticals Inc....
...kinase 4 TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Kymera Therapeutics Inc. Nurix Therapeutics Inc. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. IPO preclinical...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...Ltd. (LSE:SYNC) held about 60% of Freeline’s shares following the series C. The filing for Checkmate Pharmaceuticals Inc....
...Therapeutics Inc., Nurix Therapeutics Inc. and Inozyme Pharma Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...of cancer indications. Longitude Capital and Novo Holdings A/S led the round for Cambridge, Mass.-based Checkmate Pharmaceuticals Inc....
...MK-3475, lambrolizumab) Opdivo (Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Checkmate Pharmaceuticals Inc. Merck...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...The neurological diseases company also promoted Timothy Daly to EVP, finance from SVP. Immuno-oncology company Checkmate Pharmaceuticals Inc....
...Staff Sangamo Therapeutics Inc. Genmab A/S Kintai Therapeutics Inc. Aerie Pharmaceuticals Inc. Oasmia Pharmaceutical AB Rafael Pharmaceuticals Inc. Arvelle Therapeutics GmbH Ovid Therapeutics Inc. Checkmate Pharmaceuticals Inc. Entasis...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...COO. She was EVP commercialization and outcomes at ICON plc (NASDAQ:ICLR). Jonathan Block, Associate Editor Gilead Sciences Inc. Checkmate Pharmaceuticals Inc. BiomX...
BioCentury | Jun 12, 2019
Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

...that Brian Piper will become CFO on July 1. Mauro was most recently CMO at Checkmate Pharmaceuticals Inc....
BioCentury | Dec 14, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...late 2019. Checkmate has raised $74 million to date. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Allison Johnson CMP-001, cyt003, cyt003-qbg10, QbG10 Checkmate Pharmaceuticals Inc. Toll-like...
Items per page:
1 - 10 of 31
BioCentury | Jan 6, 2021
Management Tracks

Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more

...new role as chief corporate development officer at the diagnostics company.Robert Dolski joined immuno-oncology company Checkmate Pharmaceuticals Inc....
...the board at Radius Health Inc. (NASDAQ:RDUS). Jessica Hopfield and Tony Rosenberg stepped down from the board. BC Staff Nektar PureTech Novacyt Checkmate Pharma Radius...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...Aled Williams as CBO. Williams was most recently chief commercial officer at VectivBio AG.Oncology company Checkmate Pharmaceuticals Inc....
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...Syncona company, Orbit Biomedical Ltd., has been merged into Gyroscope (see “Syncona’s Sister Act” ). Checkmate Pharmaceuticals Inc....
...that gives it a dual listing. Targets TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Freeline Therapeutics Checkmate Pharmaceuticals Inc. Arya...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...“Crossovers Pile In” ). More IPO news Two more biotechs, Freeline Therapeutics Holdings plc and Checkmate Pharmaceuticals Inc....
...kinase 4 TLR9 - Toll-like receptor 9 Paul Bonanos, Associate Editor Kymera Therapeutics Inc. Nurix Therapeutics Inc. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. IPO preclinical...
BioCentury | Jul 21, 2020
Finance

As trio of companies enter IPO queue, four more propose terms

...Ltd. (LSE:SYNC) held about 60% of Freeline’s shares following the series C. The filing for Checkmate Pharmaceuticals Inc....
...Therapeutics Inc., Nurix Therapeutics Inc. and Inozyme Pharma Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...of cancer indications. Longitude Capital and Novo Holdings A/S led the round for Cambridge, Mass.-based Checkmate Pharmaceuticals Inc....
...MK-3475, lambrolizumab) Opdivo (Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Checkmate Pharmaceuticals Inc. Merck...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...The neurological diseases company also promoted Timothy Daly to EVP, finance from SVP. Immuno-oncology company Checkmate Pharmaceuticals Inc....
...Staff Sangamo Therapeutics Inc. Genmab A/S Kintai Therapeutics Inc. Aerie Pharmaceuticals Inc. Oasmia Pharmaceutical AB Rafael Pharmaceuticals Inc. Arvelle Therapeutics GmbH Ovid Therapeutics Inc. Checkmate Pharmaceuticals Inc. Entasis...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...COO. She was EVP commercialization and outcomes at ICON plc (NASDAQ:ICLR). Jonathan Block, Associate Editor Gilead Sciences Inc. Checkmate Pharmaceuticals Inc. BiomX...
BioCentury | Jun 12, 2019
Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

...that Brian Piper will become CFO on July 1. Mauro was most recently CMO at Checkmate Pharmaceuticals Inc....
BioCentury | Dec 14, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...late 2019. Checkmate has raised $74 million to date. Checkmate Pharmaceuticals Inc., Cambridge, Mass. Allison Johnson CMP-001, cyt003, cyt003-qbg10, QbG10 Checkmate Pharmaceuticals Inc. Toll-like...
Items per page:
1 - 10 of 31